Neurological and Related Adverse Events Associated with Pharmacokinetic Interactions of Illicit Substances of Fungal Origin with Clinical Drugs
Julia M. Salamat, Kodye L. Abbott, Patrick Flannery, Kristina Gill, Muralikrishnan Dhanasekaran, Satyanarayana R. Pondugula
July 15, 2021 DOI: 10.1201/9781003191278-10 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Keywords | Pharmacokinetics Adverse effect Pharmacology |
| Key findings | Psilocybin-containing mushrooms can cause neurological adverse events through pharmacokinetic interactions with clinical drugs. |
Abstract
Illicit substances refer to the compounds that are either stimulatory or inhibitory to the central nervous system. These compounds cause hallucinogenic effects, hence, their use has been forbidden. This chapter emphasises the psychoactive illicit substances of fungal origin. Psilocybin is present in hallucinogenic mushrooms which are also called 'magic mushrooms'. It discusses the neurological and related adverse events associated with pharmacokinetic interactions between illicit substances of fungal origin and clinical drugs in humans. The chapter also highlights insights into the future studies to further understand the underlying pharmacokinetic mechanisms of adverse neurological and related adverse events. Psilocybin is found in certain mushrooms, such as those from genus Conocybe, Gymnopilus, Panaeolus, Pluteus, and Psilocybe.